Inhibikase Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| INHIBIKASE THERAPEUTICS, INC. | ||
| Date: March 26, 2026 | By: | /s/ MARK IWICKI |
|---|---|---|
| Mark Iwicki | ||
| Chief Executive Officer | ||
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Mark Iwicki and David McIntyre, as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ MARK IWICKI | Chief Executive Officer (Principal Executive Officer) | March 26, 2026 |
| Mark Iwicki | ||
| /s/ DAVID McINTYRE | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | March 26, 2026 |
| David McIntyre | ||
| /s/ AMIT MUNSHI | Director | March 26, 2026 |
| Amit Munshi | ||
| /s/ DAVID CANNER, PH.D. | Director | March 26, 2026 |
| David Canner, Ph.D. | ||
| /s/ DENNIS BERMAN | Director | March 26, 2026 |
| Dennis Berman | ||
| /s/ ARVIND KUSH | Director | March 26, 2026 |
| Arvind Kush | ||
| /s/ ROBERTO BELLINI | Director | March 26, 2026 |
| Roberto Bellini | ||
| /s/ VINCENT AURENTZ | Director | March 26, 2026 |
| Vincent Aurentz | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.